Lei Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lei Sun has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Linlang Guo
Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
2 shared publications Run-Chang Wang
Second Clinical School, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Road, Wuhan 430030, China
2 shared publicationsYichun Tang
Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China
2 shared publicationsCun-Tai Zhang
Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publicationFeng Ma
Department of Radiation Oncology, The First People’s Hospital of Foshan, Foshan, 528000, China
1 shared publicationLing Deng
Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (1) , 213-224
Ubiquitin-specific protease 1 facilitates tumor immune escape from natural killer cells and predicts the prognosis in small cell lung cancer
Objective: Small cell lung cancer (SCLC) is commonly recognized as the most fatal lung cancer type. Despite substantial advances in immune checkpoint blockade therapies for treating solid cancers, their benefits are limited ... | Find, read and cite all the research you need on Tech Science Press
- 1 January 2025
- Published by Tech Science Press in Oncology Research
- Vol. 33 (1) , 213-224
Open AccessUbiquitin-specific protease 1 facilitates tumor immune escape from natural killer cells and predicts the prognosis in small cell lung cancer
Objective: Small cell lung cancer (SCLC) is commonly recognized as the most fatal lung cancer type. Despite substantial advances in immune checkpoint blockade therapies for treating solid cancers, their benefits are limited ... | Find, read and cite all the research you need on Tech Science Press
- Open Access
- 13 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
Background: Immune checkpoint inhibitors have changed the treatment landscape for advanced non-small cell lung cancer. However, only a small proportion of patients experience clinical benefit from ICIs. Thus, the discovery of predictive biomarkers is urgently warranted. Evidence have shown that genetic aberrations in cancer cells can modulate the tumor immune milieu. We therefore explored the association between oncogenic mutations and efficacy to ICIs in non-squamous NSCLC.Methods: We curated genomic and clinical data of 314 non-squamous NSCLC patients receiving ICIs from four independent studies for the discovery cohort. For external validation, 305 patients from an ICI-treated cohort and 1,027 patients from two non-ICI-treated cohorts were used. Relations between oncogenic mutations and outcomes of immunotherapy were examined. Multivariate Cox regression models were applied to adjust confounding factors. Further investigation on tumor antigenicity and antitumor immunity was performed in The Cancer Genome Atlas lung adenocarcinoma cohort.Results: A total of 82 oncogenes/tumor suppressor genes according to the Oncology Knowledge base database with a frequency greater than 3% were identified and investigated in the discovery cohort. Within these genes, MGA mutations were enriched in patients with durable clinical benefit (p = 0.001, false discovery rate q < 0.05). The objective response rate was also significantly higher in patients with MGA mutation (2.63-fold, p < 0.001, FDR q < 0.05). Longer progression-free survival was found in MGA-mutated patients (HR, 0.41; 95% CI, 0.23–0.73; p = 0.003), and the association remained significant after controlling for tumor mutational burden (TMB), programmed cell death ligand-1 expression, and treatment regimens. In the validation cohort, significant improvement in overall survival was found in patients harboring MGA mutation (HR, 0.39; 95% CI, 0.17–0.88; p = 0.02). Furthermore, the survival difference was not detected in non-ICI-treated cohorts. We also demonstrated that MGA mutation correlate with higher TMB, elevated neoantigen load and DNA damage repair deficiency. Gene set enrichment analysis revealed that gene sets regarding activated immune responses were enriched in MGA-mutated tumors.Conclusion: Our work provides evidence that MGA mutation can be used as a novel predictive biomarker for ICI response in non-squamous NSCLC and merits further clinical and preclinical validation.
- 13 April 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessMGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
Background: Immune checkpoint inhibitors have changed the treatment landscape for advanced non-small cell lung cancer. However, only a small proportion of patients experience clinical benefit from ICIs. Thus, the discovery of predictive biomarkers is urgently warranted. Evidence have shown that genetic aberrations in cancer cells can modulate the tumor immune milieu. We therefore explored the association between oncogenic mutations and efficacy to ICIs in non-squamous NSCLC.Methods: We curated genomic and clinical data of 314 non-squamous NSCLC patients receiving ICIs from four independent studies for the discovery cohort. For external validation, 305 patients from an ICI-treated cohort and 1,027 patients from two non-ICI-treated cohorts were used. Relations between oncogenic mutations and outcomes of immunotherapy were examined. Multivariate Cox regression models were applied to adjust confounding factors. Further investigation on tumor antigenicity and antitumor immunity was performed in The Cancer Genome Atlas lung adenocarcinoma cohort.Results: A total of 82 oncogenes/tumor suppressor genes according to the Oncology Knowledge base database with a frequency greater than 3% were identified and investigated in the discovery cohort. Within these genes, MGA mutations were enriched in patients with durable clinical benefit (p = 0.001, false discovery rate q < 0.05). The objective response rate was also significantly higher in patients with MGA mutation (2.63-fold, p < 0.001, FDR q < 0.05). Longer progression-free survival was found in MGA-mutated patients (HR, 0.41; 95% CI, 0.23–0.73; p = 0.003), and the association remained significant after controlling for tumor mutational burden (TMB), programmed cell death ligand-1 expression, and treatment regimens. In the validation cohort, significant improvement in overall survival was found in patients harboring MGA mutation (HR, 0.39; 95% CI, 0.17–0.88; p = 0.02). Furthermore, the survival difference was not detected in non-ICI-treated cohorts. We also demonstrated that MGA mutation correlate with higher TMB, elevated neoantigen load and DNA damage repair deficiency. Gene set enrichment analysis revealed that gene sets regarding activated immune responses were enriched in MGA-mutated tumors.Conclusion: Our work provides evidence that MGA mutation can be used as a novel predictive biomarker for ICI response in non-squamous NSCLC and merits further clinical and preclinical validation.
- 1 August 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (8) , 153032
ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer
- 1 August 2020
- Published by Elsevier in Pathology - Research and Practice
- Vol. 216 (8) , 153032
ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer
- Open Access
- 15 July 2020
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 20 (1) , 1-7
The predictive value of lymphocyte-to-monocyte ratio in the prognosis of acute coronary syndrome patients: a systematic review and meta-analysis
Background: The association between the lymphocyte-to-monocyte ratio (LMR) and prognosis in the patients with acute coronary syndrome (ACS) is not fully understood. We performed this systematic review and meta-analysis to evaluate the correlation between LMR and mortality or major adverse cardiac events (MACE) in patients with ACS. Methods: A systematic search was performed in PubMed, MEDLINE, EMBASE, the Cochrane Library, Scopus, and Web of science. The association between LMR and mortality/MACE was analyzed in patients with ACS. The search was updated to April 15, 2020. Results: A total of 5 studies comprising 4343 patients were included in this meta-analysis. The results showed that lower LMR predicted higher short-term mortality/MACE (hazard ratio [HR] = 3.44, 95% confidence interval [CI]: 1.46–8.14, P < 0.05) and long-term mortality/MACE (HR = 1.70, 95% CI: 1.36–2.13, P < 0.05). In the subgroup analysis, there was still statistical significance of long-term mortality/MACE in all subgroups. Conclusions: This study suggested that lower LMR value might be associated with higher short-term and long-term mortality/MACE in ACS patients. Especially for younger ACS patients, low LMR was more closely associated with poor prognosis.
- 15 July 2020
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 20 (1) , 1-7
Open AccessThe predictive value of lymphocyte-to-monocyte ratio in the prognosis of acute coronary syndrome patients: a systematic review and meta-analysis
Background: The association between the lymphocyte-to-monocyte ratio (LMR) and prognosis in the patients with acute coronary syndrome (ACS) is not fully understood. We performed this systematic review and meta-analysis to evaluate the correlation between LMR and mortality or major adverse cardiac events (MACE) in patients with ACS. Methods: A systematic search was performed in PubMed, MEDLINE, EMBASE, the Cochrane Library, Scopus, and Web of science. The association between LMR and mortality/MACE was analyzed in patients with ACS. The search was updated to April 15, 2020. Results: A total of 5 studies comprising 4343 patients were included in this meta-analysis. The results showed that lower LMR predicted higher short-term mortality/MACE (hazard ratio [HR] = 3.44, 95% confidence interval [CI]: 1.46–8.14, P < 0.05) and long-term mortality/MACE (HR = 1.70, 95% CI: 1.36–2.13, P < 0.05). In the subgroup analysis, there was still statistical significance of long-term mortality/MACE in all subgroups. Conclusions: This study suggested that lower LMR value might be associated with higher short-term and long-term mortality/MACE in ACS patients. Especially for younger ACS patients, low LMR was more closely associated with poor prognosis.
- 1 February 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (6) , 1586-1597
Diabetes Mellitus Is an Independent Risk Factor for Colorectal Cancer
Epidemiological studies have suggested positive associations between diabetes and colorectal cancer. However, the findings were inconsistent, especially regarding specific sex or cancer subsite. To conduct a systematic review with meta-analysis to examine the association of diabetes mellitus with risk of colorectal cancer and to investigate whether the association is dependent on sex, cancer subsite, race/ethnicity, or duration of diabetes. Relevant studies were identified by searching Pubmed to May 12, 2011. The reference lists of identified articles were also reviewed. Two authors independently selected the studies and extracted relevant data. The study quality was assessed. Thirty-nine studies (28 cohort studies and 11 case–control studies) were included in the final analysis. Compared with non-diabetic subjects, the pooled risk estimate of colorectal cancer for diabetic subjects was 1.29 (95% CI = 1.23–1.35). The subgroup analyses revealed that the risk was significantly increased for both genders, for every cancer subsite, and for both short duration and long duration of diabetes. Exposure to diabetes increased the risk of colorectal cancer for White and Asian, whereas there was no evidence of such an association either among Black or native Hawaiians. Our results confirmed that subjects with diabetes are at modestly increased risk of developing colorectal cancer.
- 1 February 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (6) , 1586-1597
Diabetes Mellitus Is an Independent Risk Factor for Colorectal Cancer
Epidemiological studies have suggested positive associations between diabetes and colorectal cancer. However, the findings were inconsistent, especially regarding specific sex or cancer subsite. To conduct a systematic review with meta-analysis to examine the association of diabetes mellitus with risk of colorectal cancer and to investigate whether the association is dependent on sex, cancer subsite, race/ethnicity, or duration of diabetes. Relevant studies were identified by searching Pubmed to May 12, 2011. The reference lists of identified articles were also reviewed. Two authors independently selected the studies and extracted relevant data. The study quality was assessed. Thirty-nine studies (28 cohort studies and 11 case–control studies) were included in the final analysis. Compared with non-diabetic subjects, the pooled risk estimate of colorectal cancer for diabetic subjects was 1.29 (95% CI = 1.23–1.35). The subgroup analyses revealed that the risk was significantly increased for both genders, for every cancer subsite, and for both short duration and long duration of diabetes. Exposure to diabetes increased the risk of colorectal cancer for White and Asian, whereas there was no evidence of such an association either among Black or native Hawaiians. Our results confirmed that subjects with diabetes are at modestly increased risk of developing colorectal cancer.